Nhs peg4 mal

Manufactured by Thermo Fisher Scientific

NHS-PEG4-Mal is a bifunctional crosslinking reagent that contains an N-hydroxysuccinimide (NHS) ester and a maleimide group. It can be used to conjugate amine-containing and sulfhydryl-containing molecules.

Automatically generated - may contain errors

Lab products found in correlation

Formvar carbon support film, by Ted Pella (2 mentions) Heterofunctional polyethylene glycol, by Thermo Fisher Scientific (2 mentions) Silica gel matrix, by Merck Group (1 mentions) Pd minitrap g 25 desalting column, by GE Healthcare (1 mentions) Ethylenediaminetetraacetic acid, by Merck Group (1 mentions) Phenylmethanesulfonyl fluoride pmsf, by Merck Group (1 mentions)

3 protocols using nhs peg4 mal

Heterofunctional PEG Synthesis and Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

The general reagents and precursors were purchased from Sigma-Aldrich (St. Louis, MO). Electrocompetent cells of E. coli BL21(DE3) were obtained from Lucigen (Middleton, WI). Heterofunctional polyethylene glycol with n = 4 ethylene glycol units consisting succinimidyl ester and the maleimide group (NHS-PEG₄-Mal) was obtained from Thermo Scientific (Waltham, MA). Solvents were obtained from Sigma-Aldrich (St. Louis, MO) and used without further purification. Reactions were monitored by TLC (silica gel matrix, Sigma-Aldrich). TEM analysis was performed using copper grids (400-mesh) coated with formvar/carbon support film (TedPella, USA).

Chauhan K., Hernandez-Meza J.M., Rodríguez-Hernández A.G., Juarez-Moreno K., Sengar P, & Vazquez-Duhalt R. (2018). Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer. Journal of Nanobiotechnology, 16, 17.

+ Open protocol

+ Expand

TMV-PEG4 Particle Synthesis

Check if the same lab product or an alternative is used in the 5 most similar protocols

TMV-PEG₄ particles were obtained by conjugation of NHS-PEG₄-mal (22114; Thermo Fisher) to the external surface of TMV-Lys. The reaction was performed by mixing TMV-Lys (2 mg/mL final concentration) and NHS-PEG₄-mal at 10 equiv per TMV-Lys coat protein in 0.01 M potassium phosphate buffer pH 7.4 containing 10% (v/v) DMSO; the reaction was allowed to proceed overnight at RT. Then the reaction was quenched by addition of excess glycine/L-cysteine, and quenching was allowed to proceed for 1 h at RT. The products were then purified using PD MiniTrap G-25 desalting columns (28-9180-08; GE).

Pitek A.S., Wang Y., Gulati S., Gao H., Stewart P.L., Simon D.I, & Steinmetz N.F. (2017). Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies. Molecular pharmaceutics, 14(11), 3815-3823.

+ Open protocol

+ Expand

Covalent Modification of β-Glucocerebrosidase

Check if the same lab product or an alternative is used in the 5 most similar protocols

β‐Glucocerebrosidase (Velaglucerase alfa) was obtained from Shire Pharmaceuticals (Jersey, UK). Heterofunctional polyethylene glycol (n=4 ethylene glycol units) consisting of succinimidyl ester and the maleimide group (NHS‐PEG₄‐Mal) was obtained from Thermo Scientific (Waltham, MA). TEM analysis was performed using copper grids (400‐mesh) coated with formvar/carbon support film (TedPella, USA). Ethylenediaminetetraacetic acid (EDTA), threo‐1,4‐dimercapto‐2,3‐butanediol (DTT), 4‐methylumbelliferyl β‐D‐glucopyranoside (4MU‐G), and phenylmethanesulfonyl fluoride (PMSF) were purchased from Sigma‐Aldrich (St. Louis, MO). Glucosylceramide was obtained from Avanti, Polar Lipids, Inc.

Chauhan K., Olivares‐Medina C.N., Villagrana‐Escareño M.V., Juárez‐Moreno K., Cadena‐Nava R.D., Rodríguez‐Hernández A.G, & Vazquez‐Duhalt R. (2022). Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease. Chemmedchem, 17(19), e202200384.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!